NCT07529613 Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma Status COMPLETED Phase PHASE1/PHASE2
NCT07417241 SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study Status NOT_YET_RECRUITING Phase PHASE2
NCT07371585 Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management Status RECRUITING Phase PHASE2
NCT07134153 Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases Status RECRUITING Phase PHASE1/PHASE2
NCT06548178 T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer Status NOT_YET_RECRUITING Phase PHASE2
NCT06244485 A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors Status RECRUITING Phase PHASE1
NCT06174987 A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) Status RECRUITING Phase PHASE3
NCT06135194 Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib Status RECRUITING Phase N/A
NCT05765851 A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT04686305 Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC Status RECRUITING Phase PHASE1